<DOC>
	<DOC>NCT00154050</DOC>
	<brief_summary>The study is designed to test the hypothesis that high dose candesartan treatment compared to quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent angioplasty in peripheral occlusive artery disease.</brief_summary>
	<brief_title>High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty</brief_title>
	<detailed_description>Patients are randomly assigned to treatment with either candesartan 32 mg/d or Quinapril 20 mg/d before the angioplasty. Walking distance, intima media thickness and crurobrachial pressure ratios are compared after 6 weeks, 3 months and 6 months. After 6 months an angiographic control is performed.</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Quinapril</mesh_term>
	<criteria>male and female peripheral occlusive arterial disease Stad IIb Fontaine classification patients with lesions not available for PTA renal insufficiency patients on calciumantagonists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>restenosis</keyword>
	<keyword>intima hyperproliferation</keyword>
	<keyword>stent angioplasty</keyword>
	<keyword>pain-free walking distance</keyword>
</DOC>